Patient_Reported_Outcome_Measures_in_Rheumatic_Diseases

447

Patient evaluation measure (PEM) , 337
Patient global assessment (PGA) , 133–134 ,
211 , 212
Patient reported outcome measures (PROMs)
BCTQ , 332
classifi cation , 332
CTS-6 , 336
CTS-PROMs severity scale , 339
DASH outcome , 339
defi nitions , 36
development , 37–39
diagnosis , 343–344
dimension-specifi c , 24 , 25
disease severity , 344–345
disease-specifi c , 23 , 24
evidence , 28
FMS (see Fibromyalgia syndrome (FMS) )
functional disability , 344
generic instruments , 25 , 26
gout (see Gout )
individualized instruments , 26
items and domains , 39
JIA (see Juvenile idiopathic arthritis (JIA) )
Kamath and Stothard questionnaire , 338
management outcomes , 345–347
MHQ , 336
modes , 27
modifi ed BCTQ , 335
observer reported outcomes , 21
PEM , 337
PMR , 361–362
population-specifi c , 24
predictors , 340–343
properties , 27 , 33
rating scales
checklist , 36
grading continuum , 36
Likert scale , 34–35
pictorial scale , 35
Visual Analog Scale , 35
responses , 34
selection criteria
acceptability , 29
appropriateness , 28–29
feasibility , 29
interpretability , 30
precision , 30–31
reliability , 41
responsiveness , 33
validity , 32–33
SLE (see Systemic lupus erythematosus
(SLE) )
SpA (see Spondyloarthritis (SpA) )
summary items , 26–27

symptoms , 22

target identifi cation , 347

treatment outcomes , 22

type , 27

utility measures , 27

validation , 45

acceptability and data quality , 40

construct validity , 42

content validity , 42

convergent validity , 43

criterion validity , 43

discriminant validity , 43

IRT (see Item response theory (IRT) )

item discrimination , 46

item-reduction process , 44

item response , 40

reliability , 41

scaling assumptions , 40

targeting , 40 , 41

Patient-reported experience measures (PREMs)

chronic diseases , 408–409

HRQoL , 405 , 406

meta-analysis , 406

patient satisfaction , 405

personal life impact measures , 406

quality of care , 407–408

rheumatoid arthritis , 409

UK Department of Health , 410–411

Patient-reported outcomes (PROs)

challenges , 16

clinical outcome , 8–9

clinical trials , 6–7

cost–utility analyses , 7

CTT , 12–14

defi nition , 1

direct and indirect costs , 8

disability , 2–3 , 15

ICIDH , 2

impairments , 2

IRT , 14–15

multi-item scales , 11–12

participation restriction , 3–4

population studies , 10

QALY , 7

quality assurance , 9–10

single-item instruments , 10

social complexity , 2

Patient-Reported Outcomes Measurement

Information System (PROMIS) ,

226 , 299–300

Pediatric Rheumatology Quality of Life Scale

(PRQL) , 217 , 218

Picker Institute’s hospital survey

(PPE-15) , 407

Index